Bolivia Clinical Evidence for High-Risk Devices: Section 2.4.8 Requirements and Evidence Strategy

1. Key takeaways

Section 2.4.8 of the Manual requires that, for medium-to-high risk and high-risk devices, and in particular for new products, the technical documentation includes clinical studies supporting their safety and efficacy. The provision does not prescribe specific trial design requirements or sample sizes. GRZAN’s interpretation is that Bolivia adopts an open model in which the sufficiency of the evidence is left to reviewer discretion. Companies should therefore proactively construct a complete chain of clinical evidence, combining a clinical evaluation report with literature and post-market data, rather than waiting for AGEMED to raise questions. The reason is quantitative as well as strategic: based on a practical estimate, the observation rate runs at approximately 44.4%, which means a substantial share of filings receive observations of some kind. Passively waiting for AGEMED to ask for clinical content costs more than providing it up front, because each observation round adds review time and shifts the applicant from a position of control to a position of response. A dossier that anticipates the clinical question presents the reviewer with a complete reasoning chain and shortens the path to approval. The open model rewards preparation: the applicant who defines the evidence standard and documents it is in a stronger position than one who lets the reviewer set it by question.

2. Legal basis

3. Expert insights

Insight one: the qualifier new products is the key trigger for a higher evidentiary standard. Section 2.4.8 places medium-to-high risk devices, high-risk devices and new products side by side. For mature products with a long clinical history of use, the safety case can be argued through equivalence to predicate devices and through published literature. For genuinely new products, AGEMED is more likely to require direct clinical study data, because no accumulated use history exists to draw upon. Companies should therefore assess honestly at the start of the project whether the device will be perceived as new in the Bolivian context, rather than relying on the classification of the product in other markets, since the perception of novelty drives the expected evidence intensity. The assessment and its reasoning should be documented in the project file, so that the evidence plan can be defended if AGEMED questions the depth of the package. This record also shortens the response if observations arrive, because the reasoning already exists in written form.

Insight two: foreign clinical data can be accepted, but three localization tasks must be completed. Bolivia does not provide that only domestic clinical data are acceptable, so data generated abroad can be used. However, three tasks must be completed: translation into Spanish, a statement of consistency with the approval status in the country of origin, and an argument on population applicability. The third item, population applicability, is a common observation point when omitted. Reviewers want to understand why data collected in other populations can be extrapolated to patients in Bolivia, and a dossier that addresses this explicitly is materially stronger than one that leaves the question open. Translations should be certified where possible, and the consistency statement should list the markets where the device is approved together with the status of each approval. Data drawn from populations with different characteristics should be flagged and discussed rather than left for the reviewer to discover.

Insight three: clinical evidence is linked to the risk level. The level is declared by the applicant under Section 1.7 and Section 2.4.7, and the level in turn determines how strongly Section 2.4.8 applies. This forms a self-consistent chain: declaring a lower level reduces the documentation burden, but it also carries the risk of reclassification after the fact, together with the consequences that follow from it. Companies should treat classification and clinical strategy as one decision rather than two, since the choice made on the form determines both the depth of evidence expected at review and the exposure if the declared level is later challenged. A classification decision documented once and reused across documents avoids the internal contradictions that reviewers notice quickly.

4. Practical recommendations

1. Build the evidence package in three tiers: a clinical evaluation report, a literature review and post-market data, rather than submitting a single study report and treating the clinical section as complete. The three tiers should cross-reference each other, so that each document reinforces the conclusions of the others.
2. Include the population applicability argument proactively, explaining the extrapolability of foreign data to the population of Bolivia, with reference to comparators in anatomy, clinical practice and health system context.
3. For new products, engage AGEMED early on the expected evidence intensity, so that the direction of the evidence package is agreed before resources are invested and directional rework is avoided.
4. Keep the classification rationale and the clinical strategy in one file, so that any later question about the declared level can be answered from a consistent documentary basis.

5. Verification checklist

• □ The product falls within the medium-to-high risk or high-risk range
• □ Whether the product is a new product, and what intensity of evidence that requires, has been determined
• □ The clinical evaluation report includes the equivalence route to predicate devices
• □ Foreign data have completed Spanish translation and the consistency statement
• □ The population applicability argument has been included in the dossier

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support in Bolivia for manufacturers, importers and authorized representatives, covering clinical evidence strategy, clinical evaluation reporting, dossier preparation and regulatory correspondence. For assistance with Section 2.4.8 requirements and the full registration process, contact info@grzanglobal.com.